Acarbose vs Tesofensine
A side-by-side research comparison of Acarbose and Tesofensine across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Acarbose | Tesofensine |
|---|---|---|
| Full name | Acarbose (Alpha-Glucosidase Inhibitor) | Tesofensine (Triple Monoamine Reuptake Inhibitor) |
| Category | Weight Management | Weight Management |
| Status | FDA-approved drug | Phase 3 Clinical Trial |
| Mechanism | Inhibits intestinal alpha-glucosidase enzymes, slowing the breakdown of complex carbohydrates into glucose. This flattens post-prandial glucose and insulin excursions and shifts undigested carbohydrate to the colon, feeding beneficial short-chain-fatty-acid-producing bacteria. | Blocks presynaptic reuptake of noradrenaline, dopamine, and serotonin in the hypothalamus, enhancing satiety signaling, reducing food reward, and increasing thermogenesis. |
| Molecular weight | 645.6 Da | 329.4 Da |
| Half-life | ~2 hours | 8-10 days |
| Bioavailability | Very low systemic (~2%); acts locally in the gut | High (oral ~93%) |
| Typical dose | 25-100 mg per meal | 0.25-0.5 mg |
| Frequency | With carbohydrate-containing meals | Once daily |
| Route | Oral tablet | Oral |
Acarbose reported benefits
- Flattens post-meal glucose spikes
- Improves glycemic variability
- Longevity signal (ITP data)
- Feeds beneficial gut bacteria
- Modest weight support
- Minimal systemic absorption
Tesofensine reported benefits
- Significant appetite reduction
- Increased metabolic rate
- Improved satiety signaling
- 10-12% body weight loss
- Oral administration convenience
Related comparisons
Research and educational reference only. Not medical advice.